BridgeBio Pharma, Inc. (BBIO)
74.27
-3.62
(-4.65%)
USD |
NASDAQ |
Nov 05, 16:00
74.00
-0.27
(-0.36%)
After-Hours: 20:00
BridgeBio Pharma SG&A Expense (TTM) : 709.10M for Sept. 30, 2026
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2026 | 709.10M |
| June 30, 2026 | 645.86M |
| March 31, 2026 | 588.76M |
| December 31, 2025 | 531.22M |
| September 30, 2025 | 467.92M |
| June 30, 2025 | 399.12M |
| March 31, 2025 | 329.49M |
| December 31, 2024 | 288.93M |
| September 30, 2024 | 241.73M |
| June 30, 2024 | 208.69M |
| March 31, 2024 | 185.29M |
| December 31, 2023 | 150.59M |
| September 30, 2023 | 134.87M |
| June 30, 2023 | 130.28M |
| March 31, 2023 | 130.58M |
| December 31, 2022 | 143.19M |
| September 30, 2022 | 166.08M |
| June 30, 2022 | 180.97M |
| Date | Value |
|---|---|
| March 31, 2022 | 190.52M |
| December 31, 2021 | 192.21M |
| September 30, 2021 | 174.90M |
| June 30, 2021 | 164.83M |
| March 31, 2021 | 156.83M |
| December 31, 2020 | 145.68M |
| September 30, 2020 | 143.22M |
| June 30, 2020 | 130.70M |
| March 31, 2020 | 109.72M |
| December 31, 2019 | 94.35M |
| September 30, 2019 | 59.38M |
| June 30, 2019 | 46.19M |
| March 31, 2019 | 40.10M |
| December 31, 2018 | 29.21M |
| September 30, 2018 | 29.21M |
| June 30, 2018 | 18.90M |
| March 31, 2018 | 8.007M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 1.338B |
| Ionis Pharmaceuticals, Inc. | 527.56M |
| Pfizer Inc. | 10.53B |
| Cytokinetics, Inc. | 301.02M |
| Vertex Pharmaceuticals, Inc. | 1.563B |